Prasinezumab is a new medicine in clinical trials that targets alpha-synuclein, with the aim of slowing Parkinson’s progression. While key trials did not meet their primary goals, encouraging signals keep scientific interest alive.
Discover the early symptoms of young-onset Parkinson’s through Michael’s personal story. Learn how subtle signs first appeared, why they were overlooked, and how early recognition can make a meaningful difference in living well with Parkinson’s.
